Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 93% Improvement Relative Risk Annweiler et al. Vitamin D for COVID-19 Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? Retrospective 61 patients in France Lower mortality with vitamin D (p=0.017) Annweiler et al., Nutrients, doi:10.3390/nu12113377 Favors vitamin D Favors control
Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study
Annweiler et al., Nutrients, doi:10.3390/nu12113377
Annweiler et al., Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The.., Nutrients, doi:10.3390/nu12113377
Nov 2020   Source   PDF  
  All Studies   Meta
Retrospective study finding that regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.
For those receiving regular supplementation:
Adjusted mortality hazard ratio with supplementation HR 0.07, p = 0.017.
Risk of severe COVID-19 with supplementation OR 0.08, p = 0.033.
For supplementation started after COVID-19 diagnosis:
Adjusted mortality hazard ratio HR 0.37, p = 0.28.
Risk of severe COVID-19 with supplementation OR 0.46, p = 0.4.
risk of death, 93.0% lower, RR 0.07, p = 0.02, treatment 2 of 29 (6.9%), control 10 of 32 (31.2%), NNT 4.1, adjusted per study, regular bolus supplementation.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Annweiler et al., 2 Nov 2020, retrospective, France, peer-reviewed, mean age 88.0, 7 authors, dosage 50,000IU monthly, dose varies - 50,000 IU/month, or 80,000IU/100,000IU every 2–3 months.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study Gaëlle Annweiler 1,2 , Mathieu Corvaisier 3,4 , Jennifer Gautier 3 , Vincent Dubée 1,5,6 , Erick Legrand 1,7 , Guillaume Sacco 3,8 and Cédric Annweiler 1,3,8,9,10, * on behalf of the GERIA-COVID study group 1 2 3 4 5 6 7 8 9 10 * School of Medicine, Health Faculty, University of Angers, 49045 Angers, France; (G.A.); (V.D.); (E.L.) Department of Medicine, Clinique de l’Anjou, 49044 Angers, France Department of Geriatric Medicine, Research Center on Autonomy and Longevity, University Hospital, 49933 Angers, France; (M.C.); (J.G.); (G.S.) Department of Pharmacy, Angers University Hospital, 49933 Angers, France Nantes-Angers Cancer and Immunology Research Center (CRCINA), Inserm, University of Angers, 49000 Angers, France Department of Infectious and Tropical Diseases, Angers University Hospital, 49933 Angers, France Department of Rheumatology, Angers University Hospital, 49933 Angers, France EA4638, Laboratory of Psychology of the Pays de la Loire, University of Angers, 49045 Angers, France Gérontopôle of Pays de la Loire, 44000 Nantes, France Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, the University of Western Ontario, London, ON N6A 5K8, Canada Correspondence:; Tel.: +332-4135-4725; Fax: +332-4135-4894 Received: 23 September 2020; Accepted: 28 October 2020; Published: 2 November 2020   Abstract: Background. The objective of this quasi-experimental study was to determine whether bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients. Methods. Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were included. Intervention groups were participants regularly supplemented with vitamin D over the preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group 2). The comparator group involved participants having received no vitamin D supplements (Group 3). Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement (OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological treatments of respiratory disorders. Results. The three groups (n = 77; mean ± SD, 88 ± 5 years; 49% women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to 81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer survival time than Group 3 (log-rank p = 0.015), although there was no..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop